{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001757","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.411190+00:00","generated_at":"2026-05-24T03:57:11.143194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC","bullets":["Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.","Plinabulin Phase 3 data published in Lancet Respiratory Medicine: statistically significant overall survival benefit in 2L/3L NSCLC EGFR wild-type vs docetaxel.","Agreement to sell portion of SEED shares for ~$35.4M gross proceeds; first close of $7.35M in Feb 2025.","SEED entered Eisai research collaboration with potential payments up to $1.5B; completed $24M Series A-3 first close led by Eisai.","SEED's RBM39 degrader ST-01156 granted Rare Pediatric Disease and Orphan Drug Designations by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001757","json":"https://secwatch.observer/filing/0001171843-25-001757.json","markdown":"https://secwatch.observer/filing/0001171843-25-001757.md","text":"https://secwatch.observer/filing/0001171843-25-001757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/0001171843-25-001757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/f8k_032725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:57:11.143194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}